Experimental treatment for newly diagnosed plasma cell leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing a new cell therapy called ARI0002h for people newly diagnosed with primary plasma cell leukemia, an aggressive type of multiple myeloma. It aims to see if the treatment is safe and effective as an initial therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been recently diagnosed with primary plasma cell leukemia.
- You must be able to care for yourself (ECOG score 0-2).
- You must have a life expectancy of more than 3 months.
- You should have adequate veins for the cell collection procedure (apheresis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
This trial tests a new combination of drugs (CM336, isatuximab, bortezomib, and lenalidomide) for people newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. It aims to see if this combination can help control the disease better.
This early study tests a new cell therapy called ARI0003 for people with certain aggressive B-cell lymphomas not cured by standard treatments. The goal is to see if this therapy can help when other options fail.
This trial tests a new CAR-T cell treatment that targets both CD19 and BCMA proteins on cancer cells. It may help people with multiple myeloma, plasma cell leukemia, or related cancers that have not responded to at least three prior treatments.
Hear when a new Leukemia, Plasma Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.